| 000 | 02679 a2200745 4500 | ||
|---|---|---|---|
| 005 | 20250514042518.0 | ||
| 264 | 0 | _c20021204 | |
| 008 | 200212s 0 0 eng d | ||
| 022 | _a0923-7534 | ||
| 024 | 7 |
_a10.1093/annonc/mdf287 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aItoh, K | |
| 245 | 0 | 0 |
_aRandomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cSep 2002 |
||
| 300 |
_a1347-55 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 | _aConfidence Intervals |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aJapan |
| 650 | 0 | 4 | _aLenograstim |
| 650 | 0 | 4 |
_aLymphoma, Non-Hodgkin _xdiagnosis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeutropenia _xprevention & control |
| 650 | 0 | 4 |
_aPrednisolone _xadministration & dosage |
| 650 | 0 | 4 | _aProbability |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVincristine _xadministration & dosage |
| 700 | 1 | _aOhtsu, T | |
| 700 | 1 | _aFukuda, H | |
| 700 | 1 | _aSasaki, Y | |
| 700 | 1 | _aOgura, M | |
| 700 | 1 | _aMorishima, Y | |
| 700 | 1 | _aChou, T | |
| 700 | 1 | _aAikawa, K | |
| 700 | 1 | _aUike, N | |
| 700 | 1 | _aMizorogi, F | |
| 700 | 1 | _aOhno, T | |
| 700 | 1 | _aIkeda, S | |
| 700 | 1 | _aSai, T | |
| 700 | 1 | _aTaniwaki, M | |
| 700 | 1 | _aKawano, F | |
| 700 | 1 | _aNiimi, M | |
| 700 | 1 | _aHotta, T | |
| 700 | 1 | _aShimoyama, M | |
| 700 | 1 | _aTobinai, K | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 13 _gno. 9 _gp. 1347-55 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdf287 _zAvailable from publisher's website |
| 999 |
_c12077922 _d12077922 |
||